

## A circular ink stamp from the Office of the Patent and Trademark Commissioner. The text "OFFICE" is at the top, "PATENT &amp; TRADEMARK" is at the bottom, and "COMMISSIONER" is on the right side. In the center, the date "NOV 07 2002" is stamped.

[illegible]

1. 1990年12月，在“中国—东盟”领导人非正式会议上，中国领导人正式提出建立中国—东盟自由贸易区。

[illegible]

Registered Patent Agents:  
Katherine M. Mark, Esq.  
1000 Pennsylvania Ave., N.E.  
Arlington, N.M. 87001  
Phone: (505) 763-2100  
Fax: (505) 763-2101  
Matthew J. Galloway  
Arlington, N.M. 87001  
Phone: (505) 763-2100  
Bryan A. Matlock  
March 1991  
Katherine M. Mark  
Bryan A. Matlock  
Arlington, N.M. 87001  
Phone: (505) 763-2100  
Fax: (505) 763-2101  
Matthew J. Galloway  
Arlington, N.M. 87001  
Phone: (505) 763-2100  
Fax: (505) 763-2101

1. *Pharmaceuticals*  
 2. *Medical Devices*  
 3. *Biotechnology*  
 4. *Healthcare Services*  
 5. *Medical Research*  
 6. *Health Insurance*  
 7. *Medical Education*  
 8. *Healthcare Policy*  
 9. *Medical Ethics*  
 10. *Healthcare Economics*  
 11. *Medical Law*  
 12. *Healthcare Management*  
 13. *Medical History*  
 14. *Healthcare Technology*  
 15. *Medical Innovation*  
 16. *Healthcare Reform*  
 17. *Medical Regulation*  
 18. *Healthcare Quality*  
 19. *Medical Safety*  
 20. *Healthcare Access*  
 21. *Medical Research Funding*  
 22. *Healthcare Policy Analysis*  
 23. *Medical Ethics Case Studies*  
 24. *Healthcare Economics Research*  
 25. *Medical Law Cases*  
 26. *Healthcare Management Practices*  
 27. *Medical History Research*  
 28. *Healthcare Technology Trends*  
 29. *Medical Innovation Case Studies*  
 30. *Healthcare Reform Proposals*  
 31. *Medical Regulation Frameworks*  
 32. *Healthcare Quality Improvement*  
 33. *Medical Safety Protocols*  
 34. *Healthcare Access Initiatives*  
 35. *Medical Research Funding Mechanisms*  
 36. *Healthcare Policy Implementation*  
 37. *Medical Ethics Education*  
 38. *Healthcare Economics Models*  
 39. *Medical Law Legislation*  
 40. *Healthcare Management Systems*  
 41. *Medical History Texts*  
 42. *Healthcare Technology Applications*  
 43. *Medical Innovation Challenges*  
 44. *Healthcare Reform Outcomes*  
 45. *Medical Regulation Enforcement*  
 46. *Healthcare Quality Metrics*  
 47. *Medical Safety Audits*  
 48. *Healthcare Access Barriers*  
 49. *Medical Research Funding Sources*  
 50. *Healthcare Policy Debates*  
 51. *Medical Ethics Guidelines*  
 52. *Healthcare Economics Data*  
 53. *Medical Law Cases*  
 54. *Healthcare Management Best Practices*  
 55. *Medical History Research*  
 56. *Healthcare Technology Innovations*  
 57. *Medical Innovation Case Studies*  
 58. *Healthcare Reform Proposals*  
 59. *Medical Regulation Frameworks*  
 60. *Healthcare Quality Improvement*  
 61. *Medical Safety Protocols*  
 62. *Healthcare Access Initiatives*  
 63. *Medical Research Funding Mechanisms*  
 64. *Healthcare Policy Implementation*  
 65. *Medical Ethics Education*  
 66. *Healthcare Economics Models*  
 67. *Medical Law Legislation*  
 68. *Healthcare Management Systems*  
 69. *Medical History Texts*  
 70. *Healthcare Technology Applications*  
 71. *Medical Innovation Challenges*  
 72. *Healthcare Reform Outcomes*  
 73. *Medical Regulation Enforcement*  
 74. *Healthcare Quality Metrics*  
 75. *Medical Safety Audits*  
 76. *Healthcare Access Barriers*  
 77. *Medical Research Funding Sources*  
 78. *Healthcare Policy Debates*  
 79. *Medical Ethics Guidelines*  
 80. *Healthcare Economics Data*  
 81. *Medical Law Cases*  
 82. *Healthcare Management Best Practices*  
 83. *Medical History Research*  
 84. *Healthcare Technology Innovations*  
 85. *Medical Innovation Case Studies*  
 86. *Healthcare Reform Proposals*  
 87. *Medical Regulation Frameworks*  
 88. *Healthcare Quality Improvement*  
 89. *Medical Safety Protocols*  
 90. *Healthcare Access Initiatives*  
 91. *Medical Research Funding Mechanisms*  
 92. *Healthcare Policy Implementation*  
 93. *Medical Ethics Education*  
 94. *Healthcare Economics Models*  
 95. *Medical Law Legislation*  
 96. *Healthcare Management Systems*  
 97. *Medical History Texts*  
 98. *Healthcare Technology Applications*  
 99. *Medical Innovation Challenges*  
 100. *Healthcare Reform Outcomes*

- \* *Antennipedia*, 1994, Madrid, 3
- \* *Antennipedia*, 1995, Madrid, 3
- \* *Antennipedia*, 1996, Madrid, 3
- \* *Antennipedia*, 1997, Madrid, 3

**WRITER'S DIRECT NUMBER:**  
(202) 371-2625  
**INTERNET ADDRESS:**  
ESTIEFF@SKGE.COM

*Art Unit 1646*

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Statement of the Substance of the Interview; and
2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe  
Attorney for Applicants  
Registration No. 36,688

EKS/PSC/lam  
Enclosures

:ODMAMHODMASKGE DC1:72933,1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

YU *et al.*

Appl. No. 09/333,966

Filed: June 16, 1999

For: **Death Domain Containing  
Receptors**

Confirmation No.: 4780

Art Unit: 1646

Examiner: Ulm, John D.

Atty. Docket: 1488.0310005/EKS/PSC

TECH CENTER 1600-2900

NOV 08 2002

RECEIVED

**Statement of the Substance of the Interview**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants provide herein a statement of the substance of the interview conducted between the Examiner, the Supervisory Examiner, the Patent Practice Specialist, Applicants' representatives and Dr. Thi-Sau Migone held on October 9, 2002.

During the interview, Applicants discussed the teachings found in several references cited by Applicants' in support of the utility of the claimed invention. In particular, the teachings found in Warzocha *et al.*, *Biochem. Biophys. Res. Comm.* 242:376-379 (1998) and Migone *et al.*, *Immunity* 16:479-492 (2002) were discussed.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. If extensions of time under 37 C.F.R. § 1.136 other than those otherwise provided for herewith are required to prevent abandonment of the present patent application, then such extensions of time are hereby petitioned, and any fees therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe  
Attorney for Applicants  
Registration No. 36, 688